These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 18945688)

  • 41. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
    Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
    Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
    Liang JA; Sun LM; Lin MC; Chang SN; Sung FC; Muo CH; Kao CH
    Oncologist; 2012; 17(7):986-91. PubMed ID: 22723508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of finasteride on prostate specific antigen: review of available data.
    Guess HA; Gormley GJ; Stoner E; Oesterling JE
    J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship of serum sex-steroid hormones and prostate volume in African American men.
    Joseph MA; Wei JT; Harlow SD; Cooney KA; Dunn RL; Jaffe CA; Montie JE; Schottenfeld D
    Prostate; 2002 Dec; 53(4):322-9. PubMed ID: 12430143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial.
    Chadid S; Barber JR; Nelson WG; Gurel B; Lucia MS; Thompson IM; Goodman PJ; Stanczyk FZ; Parnes HL; Lippman SM; De Marzo AM; Platz EA
    Prostate; 2020 Aug; 80(11):895-905. PubMed ID: 32506665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum sex steroids, gonadotrophins and sex hormone-binding globulin in prostatic hyperplasia.
    Ansari MA; Begum D; Islam F
    Ann Saudi Med; 2008; 28(3):174-8. PubMed ID: 18500180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study.
    Detering M; Steels E; Koyyalamudi SR; Allifranchini E; Bocchietto E; Vitetta L
    Biofactors; 2017 Nov; 43(6):789-800. PubMed ID: 29048765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.
    Hara N; Ishizaki F; Saito T; Nishiyama T; Kawasaki T; Takahashi K
    Urology; 2013 Feb; 81(2):376-80. PubMed ID: 23374809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sex hormones and the risk of incident prostate cancer.
    Daniels NA; Nielson CM; Hoffman AR; Bauer DC;
    Urology; 2010 Nov; 76(5):1034-40. PubMed ID: 20451981
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
    Eliassen AH; Missmer SA; Tworoger SS; Spiegelman D; Barbieri RL; Dowsett M; Hankinson SE
    J Natl Cancer Inst; 2006 Oct; 98(19):1406-15. PubMed ID: 17018787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer.
    Kumazawa T; Tsuchiya N; Wang L; Sato K; Kamoto T; Ogawa O; Nakamura A; Kato T; Habuchi T
    Int J Cancer; 2004 May; 110(1):140-4. PubMed ID: 15054879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
    de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH
    Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Kristal AR; Arnold KB; Schenk JM; Neuhouser ML; Weiss N; Goodman P; Antvelink CM; Penson DF; Thompson IM
    J Urol; 2007 Apr; 177(4):1395-400; quiz 1591. PubMed ID: 17382740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study.
    Parsons JK; Palazzi-Churas K; Bergstrom J; Barrett-Connor E
    J Urol; 2010 Sep; 184(3):1040-4. PubMed ID: 20643424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The protective effect of diabetes mellitus against prostate cancer: role of sex hormones.
    Baradaran N; Ahmadi H; Salem S; Lotfi M; Jahani Y; Baradaran N; Mehrsai AR; Pourmand G
    Prostate; 2009 Dec; 69(16):1744-50. PubMed ID: 19676082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community.
    Roberts RO; Lieber MM; Jacobson DJ; Girman CJ; Jacobsen SJ
    Mayo Clin Proc; 2005 Jun; 80(6):759-64. PubMed ID: 15948299
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
    Hall MC; Roehrborn CG; McConnell JD
    Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
    Unger JM; Till C; Thompson IM; Tangen CM; Goodman PJ; Wright JD; Barlow WE; Ramsey SD; Minasian LM; Hershman DL
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27565902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.